Paracetamol, Ibuprofen May Soon Be Available At General Stores As India Reviews First List Of OTC Drugs
Last Updated:
A committee has proposed that India needs to develop legal provisions, eligibility for considering drug as OTC and special labelling similar to those for prescription medicines
A total of 27 prescription-only medicines, including levocetrizine, ibuprofen and paracetamol will soon be sold at medical and general stores as over-the-counter (OTC) drugs, News18 has learnt.
The list of 27 drugs includes the names of generic formulations and the strength of doses allowed to be sold without a prescription.
Currently, India lacks a comprehensive set of regulations governing the distribution, marketing, and consumption of OTC drugs. In May, drug regulator Central Drugs Standard Control Organisation (CDSCO) constituted a sub-committee to examine matters regarding the amendment of the Drugs Rules to incorporate necessary provisions for drugs to be declared as over-the-counter (OTC), in line with a recommendation of the Drugs Technical Advisory Board (DTAB) meeting. Now, the panel has submitted the report, and DTAB will deliberate to move on moving forward.
'The subcommittee has finely balanced and submitted the report containing almost 27 generic names of formulations for the top therapeutic segment. These formulations are top-selling and best in the safety profile of that category. For instance, Levocetirizine is best to treat allergies, ibuprofen is best for painkillers and paracetamol for anti-pyretic use," a senior official at the Ministry of Health and Family Welfare, privy to the development, told News18.
The sub-panel has also mentioned the strength of the medicines which should be available in the OTC category. 'It would be damaging if people end up popping painkiller ibuprofen in higher doses. Hence, the idea is to keep the moderate or mild dose available without prescription."
'Legal provisions to be enabled under Drugs Rules, 1945 along with the manner of submitting application, requirements for considering a drug as an OTC, Labelling requirements, etc and incorporation of a separate Schedule as enumerated under section 7 of the report," said the government document containing agenda for discussion on upcoming DTAB meeting.
The DTAB meeting is expected to convene in April. However, the final decision may take several meetings as the central government needs to design a full plan before it decides to shift prescription medicines into the OTC category.
The sub-committee was headed by Dr Anupam Prakash, Director and Professor of Medicine, Lady Hardinge Medical College, Delhi. The panel has other members including as Dr Umesh D Suranagi from Director General of Health Services (DGHS), Paediatrician Dr Ratan Kumar Gupta from Vardhman Mahavir Medical College & Safdarjung Hospital and Dr Bikash Medhi, Department of Pharmacology, Post Graduate Institute of Medical Education & Research (PGIMER).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
12 hours ago
- News18
India Bets On Jan Aushadhi Kendras For HPV Vaccine To Prevent Cervical Cancer, Adds 116 New Drugs
Last Updated: The list also includes medicines for heart diseases, diabetes, epilepsy, apart from various other types of cancers The government's plan a roll out a nationwide HPV vaccination drive for girls to prevent cervical cancer remains stalled due to insufficient vaccine stock. To tide over the problem, the Narendra Modi government's flagship affordable generic drugs scheme, Jan Aushadhi, has now decided to include the HPV or Human Papillomavirus among 116 new medicines being added to its portfolio. The final list of medicines, accessed by News18, lists the recombinant HPV quadrivalent vaccine, which is effective against diseases caused by HPV types 6, 11, 16, and 18. '…used for the prevention of HPV-associated cancers, such as cervical, vaginal, vulvar, and anal cancer", mentions the document in the category of usage of the drug. The vaccine is expected to be available at subsidised rates through Jan Aushadhi outlets. The objective of the planned offering is to offer timely access, even as the national rollout remains uncertain. 'While the meeting to discuss the status of the roll-out of the nationwide HPV vaccination campaign for girls (aged 9 to 14 years) is expected to take place during the last week of June, there is no update from the Serum Institute of India (SII) on the requested quantity of vaccine doses. Without them, we cannot decide timelines or go ahead," a senior government official told News18. Meanwhile, the Union government is trying to expand access to HPV vaccines via Prime Minister Narendra Modi's flagship Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP). 'The scheme has just rolled out the tender for marketing the HPV vaccine as part of the initiative to add 116 more medicines to its existing bouquet of over 2,100 drugs and 315 surgical and medical devices," another senior government official said, adding that the price of the vaccine available at Jan Aushadhi retail outlets may not be steeply discounted. However, it remains unclear how the tendering procedure will work as in India, only the Serum Institute of India is currently the licensed manufacturer of the HPV vaccine. For the private market in India, the HPV vaccine from SII — Cervavac — typically costs Rs 4,000 per dose. Other Medicines on the List The Jan Aushadhi scheme offers generic drugs priced at 50–90 per cent lower than their branded counterparts in the market. The new list of medicines will be available at 16,500 Jan Aushadhi Kendras across India by September. 'It takes three to six months to complete the procurement procedure and bring medicines onto the retail shelf. The list was finalised in March, and now the tendering process is underway," the second official said. A significant portion of the medicines being added are for the treatment of heart disease and diabetes — two of India's most pressing health challenges. While India is often called the 'Diabetes Capital of the World,' with over 74 million adults affected, it also accounts for approximately 60 per cent of the world's heart disease burden. The list also includes several cancer drugs, including Ibrutinib, used in the treatment of blood cancer and costing between Rs 7,000 and Rs 9,500, which severely hurts the pocket of middle and lower-income class patients and families. Also, the list includes Abiraterone Acetate, a drug used in the treatment of prostate cancer, blood cancer, Hodgkin's disease, and also prescribed in some cases of sickle cell anaemia. A bottle of 60 tablets of the drug costs around Rs 35,000. With inclusion under the scheme, the prices of these drugs—in their generic version—are expected to fall by at least 50 per cent. Several other drugs for therapeutic categories such as the central nervous system, epilepsy and seizures, chronic obstructive pulmonary disease (COPD), anti-allergy and bone deficiencies are also part of the list. In March, Union health minister JP Nadda said the scheme is helping over 10 lakh people access affordable medicines, leading to cumulative savings of Rs 30,000 crore. While the scheme has been helping those, who cannot afford branded medicines, if it manages to offer quality cancer drugs and the HPV vaccine at discounted prices, it could set a significant benchmark for public health affordability and access. First Published:
News18
a day ago
- News18
Can Masturbation Actually Improve Your Relationship?
Last Updated: Masturbation, a topic frequently shrouded in privacy, holds potential beyond solitary pleasure Sex may permeate our popular culture, but conversations about it are still associated with stigma and shame in Indian households. As a result, most individuals dealing with sexual health issues or trying to find information about sex often resort to unverified online sources or follow the unscientific advice of their friends. To address the widespread misinformation about sex, is running this weekly sex column, titled 'Let's Talk Sex'. We hope to initiate conversations about sex through this column and address sexual health issues with scientific insight and nuance. In this article, we will explain how personal desires might not only enrich your individual well-being but also strengthen your relationship. In the intricate tapestry of human relationships, intimacy often emerges as a cornerstone of connectivity and fulfilment. As you navigate the complexities of partnership, you may wonder about the role personal habits play in enhancing mutual satisfaction. Masturbation, a topic frequently shrouded in privacy, holds potential beyond solitary pleasure. Engaging in masturbation triggers the release of several hormones, including dopamine and oxytocin, often referred to as the 'feel-good" hormones. Dopamine is a neurotransmitter that plays a critical role in the brain's reward system, enhancing pleasure and motivation. Meanwhile, oxytocin, sometimes called the 'cuddle hormone", is associated with social bonding and relaxation. These hormones can lead to enhanced mood and reduced stress, potentially fostering a more positive outlook in your relationship. Masturbation also has notable physical benefits. It can increase blood flow, which contributes to improved cardiovascular health. The endorphins released during masturbation act as natural pain relievers, potentially alleviating minor aches and discomforts. Furthermore, the relaxation induced by hormonal release during orgasm can lead to better sleep quality. Adequate rest is fundamental in maintaining emotional balance, which is crucial for healthy interpersonal relationships. advetisement Through masturbation, individuals gain a deeper understanding of their own bodies and sexual preferences. This self-awareness can translate into more confident and satisfying intimate experiences with partners. Knowing what brings you pleasure allows for more open and effective communication, ultimately enhancing mutual satisfaction within the relationship. By exercising sexual autonomy, individuals can nurture self-confidence, which often reflects positively in their interactions with partners. In an era where stress and anxiety are prevalent, masturbation serves as a natural stress-relief mechanism. The process helps in reducing cortisol levels, the stress hormone, thereby calming the mind and promoting relaxation. This stress reduction can lead to improved interactions with your partner, as you are likely to be more present and patient. Incorporating masturbation into a self-care routine can act as a proactive measure to maintain mental well-being, positively impacting the dynamics of your relationship. Masturbation and Relationship Satisfaction Masturbation is often viewed merely as a personal activity, yet its potential impact on relationship satisfaction is increasingly being recognized. Engaging in self-pleasure can help individuals better understand their own bodies, leading to improved sexual self-awareness. By discovering personal preferences and what brings physical pleasure, individuals can communicate these insights to their partners more effectively. This open dialogue fosters intimacy and mutual satisfaction, forming a foundation for a more fulfilling sexual relationship. One of the key pillars of a healthy relationship is communication. When partners are open about their solo sexual activities, it can demystify the subject of masturbation, reducing shame or taboo. This transparency encourages an open-minded approach toward sexual exploration within the relationship. Discussing masturbation can also break down barriers, leading to more candid conversations about sexual needs and desires. Such openness not only enhances trust but also aligns sexual expectations between partners, contributing to overall relationship harmony. Surprisingly, engaging in regular masturbation might actually increase your desire for partnered sexual activities. This is because masturbation aids in maintaining sexual health by keeping sexual organs active, boosting libido, and releasing sexual tension. When partners feel sexually satisfied individually, they are more likely to bring that energy into shared experiences. This creates a positive cycle where self-pleasure complements rather than competes with partnered intimacy, potentially leading to an enriched sexual relationship. Can Masturbation Improve Your Relationship? Masturbation, can surprisingly contribute to strengthening relationships in various ways. By engaging in self-exploration, individuals gain a deeper understanding of their own bodies and desires. This personal insight can be a powerful tool for enhancing intimacy with a partner. When you know what brings you pleasure, you are better equipped to communicate these preferences, fostering a more fulfilling and open sexual relationship. advetisement Moreover, masturbation can release stress and tension, which can positively impact your overall mood and behaviour. Being more relaxed and content enables you to be more present and emotionally available to your partner, enhancing the quality of your interactions. Such stress-relief benefits can significantly contribute to a harmonious relationship dynamic. Lastly, maintaining personal sexual health can contribute to individual well-being, which inevitably benefits the relationship as a whole. Masturbation offers a safe outlet for sexual expression, reducing anxiety and promoting self-awareness. A healthier, happier individual is more likely to contribute positively to a relationship, creating a balanced and supportive partnership. By normalizing conversations around masturbation, couples can break down barriers that often lead to dissatisfaction or misunderstandings. This transparency nurtures a climate of mutual respect and acceptance, essential components of any healthy relationship. Conclusion top videos View All In conclusion, embracing masturbation as a natural and beneficial aspect of your relationship can lead to enhanced mutual understanding and satisfaction. By breaking the stigma and openly discussing individual needs and preferences, you foster a more intimate, honest connection with your partner. Self-exploration not only supports personal well-being but also enriches your shared sexual experiences, creating a more fulfilling partnership. As you navigate the complexities of intimacy, remember that recognizing and respecting each other's sexuality in all its forms can be a powerful tool in strengthening your bond, ultimately contributing to a healthier and more resilient relationship. About the Author Prof (Dr) Saransh Jain The News18 Lifestyle section brings you the latest on health, fashion, travel, food, and culture — with wellness tips, celebrity style, travel inspiration, and recipes. Also Download the News18 App to stay updated! tags : lets talk sex Location : New Delhi, India, India First Published: June 08, 2025, 19:42 IST News lifestyle Let's Talk Sex | Can Masturbation Actually Improve Your Relationship?
News18
2 days ago
- News18
81,000 Vials, Rs 24 Crore In 3 Months: Weight Loss Drug Mounjaro Sales Triple As Patients Shift To Higher Dose
With three months since its launch in India, according to latest Pharmatrac data, Mounjaro clocked Rs 12.6 crore in sales in May 2025—a threefold increase from March In a sign of rising adoption, sales of Mounjaro—the breakthrough weight loss and type 2 diabetes drug—have nearly tripled in the last two months, data shows. American drugmaker Eli Lilly launched Mounjaro in India on March 20, triggering immediate frenzy, especially among those looking to achieve weight loss and glucose control. Doctors told News18 they were flooded with requests from patients eager to start Mounjaro or learn more about its benefits. With three months since its launch in India, according to latest Pharmatrac data, Mounjaro clocked Rs 12.6 crore in sales in May 2025—a threefold increase from March. The higher dosage form of five milligram, in particular, more than doubled in value and quantity sales between April and May, indicating a strong trend of patient progression to the next stage of treatment. As per the medical protocol, patients start with lower dosage of 2.5 milligram weekly dose and upgrade to 5 milligram after four weeks. 'This clinical shift is clearly reflected in market numbers. Five mg pack sales jumped from Rs 3.08 crore in April to Rs 7.53 crore in May, while unit sales rose from over 9,300 to over 22,900," Sheetal Sapale, vice-president (commercial), Pharmatrac, told News18. 'Looking at these trends and the acceptance of this therapy—by physicians as well as patients—along with the affordable pricing of Rs 18,000 to Rs 22,000 per month dosage indicates a definite pick up in consumption." The total market for Mounjaro has reached Rs 23.94 crore over the past three months, selling more than 81,000 vials of the drug—signalling growing adoption in diabetes care protocols. According to Dr Anoop Misra, chairman, Fortis C-DOC Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology, clinical use of Mounjaro in India closely reflects the trends observed in the data. 'A substantial number of patients are being initiated at 2.5 mg, with a timely escalation to 5 mg in line with recommended protocols. This pattern suggests good tolerability and early clinical efficacy in glycemic control and weight reduction." Misra told News18: 'With growing familiarity and broader access, increased use of higher doses (7.5 mg and above) is likely, especially in patients requiring enhanced metabolic outcomes." The injectable drug is approved by India's apex drug regulatory body, Central Drugs Standard Control Organisation (CDSCO). Mounjaro is a once-weekly injection priced at Rs 4,375 for a 5 mg vial and Rs 3,500 for a 2.5 mg vial, making the monthly expenditure around Rs 14,000-Rs 17,500. The drug is claimed to be 80 per cent cheaper than in the United States. Entry-Level Dosage Sales Plateau Mounjaro, the brand name for Tirzepatide, a once-weekly injectable, is a first-in-class medication that combines the effects of two naturally occurring hormones: GIP (Gastric Inhibitory Polypeptide) and GLP-1 (Glucagon-Like Peptide-1). Data shows that the 2.5mg dose of Mounjaro—generally prescribed as the starting regimen for type 2 diabetes patients or those looking to shed weight—has shown signs of 'plateauing growth". This trend confirms a gradual shift to higher doses. The sales value for the 2.5 mg injection rose marginally from Rs 4.80 crore in April to Rs 5.08 crore in May, after a steeper increase from Rs 1.42 crore in March. The data shows that the unit sales also reflect this trend, increasing from 5,400 in March to 18,270 in April, but only marginally to 19,350 in May. While the 2.5 mg variant remains essential for entry-level patient initiation, its month-on-month growth may continue to taper off as the patient base matures and advances to the next phase of dosing.
